Skip to main content

Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma.

Publication ,  Journal Article
Magee, KE; Kelsey, CE; Kurzinski, KL; Ho, J; Mlakar, LR; Feghali-Bostwick, CA; Torok, KS
Published in: Arthritis research & therapy
January 2013

The purpose of this study was to evaluate the presence and levels of interferon-gamma inducible protein-10 (IP-10) in the plasma and skin of pediatric localized scleroderma (LS) patients compared to those of healthy pediatric controls and to determine if IP-10 levels correlate to clinical disease activity measures.The presence of IP-10 in the plasma was analyzed using a Luminex panel in 69 pediatric patients with LS and compared to 71 healthy pediatric controls. Of these patients, five had available skin biopsy specimens with concurrent clinical and serological data during the active disease phase, which were used to analyze the presence and location of IP-10 in the skin by immunohistochemistry (IHC).IP-10 levels were significantly elevated in the plasma of LS patients compared to that of healthy controls and correlated to clinical disease activity measures in LS. Immunohistochemistry staining of IP-10 was present in the dermal infiltrate of LS patients and was similar to that found in psoriasis skin specimens, the positive disease control.Elevation of IP-10 levels in the plasma compared to those of healthy controls and the presence of IP-10 staining in the affected skin of LS patients indicates that IP-10 is a potential biomarker in LS. Furthermore, significant elevation of IP-10 in LS patients with active versus inactive disease and correlations between IP-10 levels and standardized disease outcome measures of activity in LS strongly suggest that IP-10 may be a biomarker for disease activity in LS.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Arthritis research & therapy

DOI

EISSN

1478-6362

ISSN

1478-6354

Publication Date

January 2013

Volume

15

Issue

6

Start / End Page

R188

Related Subject Headings

  • Scleroderma, Localized
  • Male
  • Immunohistochemistry
  • Immunoassay
  • Humans
  • Female
  • Child
  • Chemokine CXCL10
  • Biomarkers
  • Arthritis & Rheumatology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Magee, K. E., Kelsey, C. E., Kurzinski, K. L., Ho, J., Mlakar, L. R., Feghali-Bostwick, C. A., & Torok, K. S. (2013). Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma. Arthritis Research & Therapy, 15(6), R188. https://doi.org/10.1186/ar4378
Magee, Kelsey E., Christina E. Kelsey, Katherine L. Kurzinski, Jonhan Ho, Logan R. Mlakar, Carol A. Feghali-Bostwick, and Kathryn S. Torok. “Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma.Arthritis Research & Therapy 15, no. 6 (January 2013): R188. https://doi.org/10.1186/ar4378.
Magee KE, Kelsey CE, Kurzinski KL, Ho J, Mlakar LR, Feghali-Bostwick CA, et al. Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma. Arthritis research & therapy. 2013 Jan;15(6):R188.
Magee, Kelsey E., et al. “Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma.Arthritis Research & Therapy, vol. 15, no. 6, Jan. 2013, p. R188. Epmc, doi:10.1186/ar4378.
Magee KE, Kelsey CE, Kurzinski KL, Ho J, Mlakar LR, Feghali-Bostwick CA, Torok KS. Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma. Arthritis research & therapy. 2013 Jan;15(6):R188.

Published In

Arthritis research & therapy

DOI

EISSN

1478-6362

ISSN

1478-6354

Publication Date

January 2013

Volume

15

Issue

6

Start / End Page

R188

Related Subject Headings

  • Scleroderma, Localized
  • Male
  • Immunohistochemistry
  • Immunoassay
  • Humans
  • Female
  • Child
  • Chemokine CXCL10
  • Biomarkers
  • Arthritis & Rheumatology